A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

Trial Profile

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Therapeutic Use
  • Acronyms FIT; HAEM 3426
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 21 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
    • 21 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
    • 11 Aug 2017 This trial was completed in Austria, according to European Clinical Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top